Efficacy of pharmacological treatment of dystonia: Evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options

European Journal of Neurology

Volumn 11, Issue 6, 2004, Pages 361-370

  Balash, Y ^a,b   Giladi, N ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Huntington's disease; Movement disorders; Multiple system atrophy; Parkinson's disease; Wilson's disease

Indexed keywords

ALCOHOL; APOMORPHINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BROMOCRIPTINE; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; LITHIUM; LORAZEPAM; MEXILETINE; NABILONE; PERPHENAZINE; RILUZOLE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TETRAHYDROBIOPTERIN; TIAPRIDE; TRIHEXYPHENIDYL; ANTIPARKINSON AGENT;

ASTHENIA; BLEPHAROSPASM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DYSPHAGIA; DYSPHONIA; DYSTONIA; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SIDE EFFECT; SPASMODIC TORTICOLLIS; TREATMENT FAILURE; WRITER CRAMP; CLASSIFICATION; DRUG SCREENING; DRUG THERAPY; MEDLINE; TREATMENT OUTCOME;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DRUG EVALUATION; DRUG THERAPY; DYSTONIA; EVIDENCE-BASED MEDICINE; HUMANS; MEDLINE; TREATMENT OUTCOME;

EID: 3142758463     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.00845.x     Document Type: Review

References (94)

1. Adler CH (2000). Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms. Postgrad Med 108:151-160.
2. Ahmad S, Meeran MK (1979). Treatment of spasmodic torticollis with diazepam. Br Med J 1(6156):127.
3. Albright AL, Barry MJ, Fasick P et al. (1996). Continuous intrathecal baclofen infusion for symptomatic generalized dystonia. Neurosurgery 38:934-938.
4. Anca MH, Falic Zaccai T, Badarna S et al. (2003). Natural history of Oppenheim's Dystonia (DYT1) in Israel. J Child Neurol 18:325-330.
5. Arlazoroff A, Klein C, Meiner Z et al. (1991). Tiapride as treatment for certain patients with idiopathic torsion dystonia. Eur Neurol 31:356-359.
6. Biary N, Koller W (1985). Effect of alcohol on dystonia. Neurology 35:239-243.
7. Blackie JD, Lees AJ (1990). Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 53:640-643.
8. Blitzer A, Brin MF, Stewart CF (1998). Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108:1435-1441.
9. Braham J, Sarova-Pinhas I (1973). Apomorphine in dystonia musculorum deformans. Lancet 1:423-432.
10. Brans JW, Lindeboom R, Snoek JW et al. (1996). Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double blind controlled trial. Neurology 46:1066-1072.
11. Brashear A, Lew MF, Dykstra DD et al. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53:1439-1446.
12. Bressman SB (2000). Dystonia update. Clin Neuropharmacol 23:239-251.
13. Brin MF, Lew MF, Adler CH et al. (1999). Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431-1438.
14. Burbaud P, Guehl D, Lagueny A et al. (1998). A pilot trial of clozapine in the treatment of cervical dystonia. J Neurol 245:329-331.
15. Burke RE, Fahn S, Marsden CD (1986). Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36:160-164.
16. Cooper IS (1972). Levodopa-induced dystonia. Lancet 2:1317-1318.
17. Couper-Smartt J (1973). Lithium in spasmodic torticollis. Lancet 2:741-742.
18. Eldridge R, Kanter W, Koerber T (1973). Letter: Levodopa in dystonia. Lancet 2:1027-1028.
19. Fahn S (1983). High dosage anticholinergic therapy in dystonia. Neurology 33:1255-1261.
20. Fahn S, List T, Moskowitz CB et al. (1985). Double blind controlled study of botulinum toxin for blepharospasm. Neurology 35:271.
21. Fink JK, Ravin P, Argoff CE et al. (1989). Tetrahydrobiopterin administration in biopterin-deficient progressive dystonia with diurnal variation. Neurology 39:1393-1395.
22. Ford B, Greene P, Louis ED et al. (1996). Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 53:1241-1246.
23. Fox SH, Kellett M, Moore AP et al. (2002). Randomised, double blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145-149.
24. Garg BP (1982). Dystonia musculorum deformans: implications of therapeutic response to levodopa and carbamazepine. Arch Neurol 39:376-377.
25. Gelb DJ, Lowenstein DH, Aminoff MJ (1989). Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39:80-84.
26. Gibbs SR, Blitzer A (2000). Botulinum toxin for the treatment of spasmodic dysphonia. Otolaryngol Clin North Am 33:879-894.
27. Giladi N, Melamed E (1999). Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism. Mov Disord 14:158-159.
28. Grassi E, Latorraca S, Piacentini S et al. (2000). Risperidone in idiopathic and symptomatic dystonia: preliminary experience. Neurol Sci 21:121-123.
29. Greene P (1992a). Baclofen in the treatment of dystonia. Clin Neuropharmacol 15:276-288.
30. Greene PE, Fahn S (1992b). Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 7:48-52.
31. Greene P, Shale H, Fahn S (1988). Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3:46-60.
32. Greene P, Kang U, Fahn S et al. (1990). Double blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40:1213-1218.
33. Harel D, Giladi N (1990). Amelioration of severe torsion dystonia with perphenazine. Isr J Med Sci 26:590-592.
34. Hongladarom T (1973). Levodopa in dystonia musculorum deformans. Lancet 1:1114.
35. Hou JG, Ondo W, Jankovic J (2001). Intrathecal baclofen for dystonia. Mov Disord 16:1201-1202.
36. Hughes AJ, Lees AJ, Marsden CD (1991). Paroxysmal dystonic head tremor. Mov Disord 6:85-86.
37. Isgreen WP, Fahn S, Barrett RE et al. (1976). Carbamazepine in torsion in dystonia. Adv Neurol 14:411-416.
38. Jaffe MS, Nienstedt LJ (2001). Intrathecal baclofen for generalized dystonia: a case report. Arch Phys Med Rehabil 82:853-855.
39. Jancovic J, Hallett M (1994). Therapy with Botulinum Toxin. Marcel Dekker, New York.
40. Jankovic J (1982). Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 11:41-47.
41. Jankovic J, Beach J (1997). Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358-362.
42. Jankovic J, Ford J (1983). Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402-411.
43. Jankovic J, Orman J (1987). Botulinum A toxin for cranial-cervical dystonia: a double blind, placebo controlled study. Neurology 37:616-623.
44. Jankovic J, Orman J (1988). Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38:391-394.
45. Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA (1997). Drug-induced movement disorders. Drug Saf 16:180-204.
46. Jost WH (2001). Evidence-based medicine (EBM). J Neurol 248:1S-2S.
47. Koller WC, Biary N (1983). Lithium ineffective in dystonia. Ann Neurol 13:579-580.
48. Krack P, Vercueil L (2001). Review of the functional surgical treatment of dystonia. Eur J Neurol 8:389-399.
49. Lal S (1989). Improvement in spasmodic torticollis following treatment and withdrawal from high dose lorazepam - clinical observations. Prog Neuropsychopharmacol Biol Psychiatry 13:531-535.
50. Langkafel M, Heinz A, Schols L et al. (1991). Apomorphine-test in dystonia. J Neural Transm Park Dis Dement Sect 3:293-295.
51. Lees A, Shaw KM, Stern GM (1976). Letter: Bromocriptine and spasmodic torticollis. Br Med J 1:1343.
52. Lew MF, Adornato BT, Duane DD et al. (1997). Botulinum toxin type B: a double blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49:701-707.
53. LeWitt PA, Miller LP, Levine RA et al. (1986). Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology 36:760-764.
54. Lorentz IT, Subramaniam SS, Yiannikas C (1991). Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov Disord 6:145-150.
55. Lucetti C, Nuti A, Gambaccini G et al. (2000). Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol 23:186-189.
56. Marsden CD, Quinn NP (1990). The dystonias. Neurological disorders affecting 20000 people in Britain. Br Med J 300:139-144.
57. Marsden CD, Marion MH, Quinn N (1984). The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 47:1166-1173.
58. Marti-Masso JF, Obeso JA, Carrera N et al. (1982). Lithium therapy in torsion dystonia. Ann Neurol 11:106-107.
59. Miyasaki JM, Martin W, Suchowersky O et al. (2002). Practice parameter: initiation of treatment for Parkinson's disease. An evidence-based review. Review of the quality standards subcommittee of the American Academy of Neurology. Neurology 58:11-17.
60. Moore AP, Blumhardt LD (1991). A double blind trial of botulinum toxin 'A' in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry 54:813-816.
61. Muller J, Wenning GK, Wissel J et al. (2002). Riluzole therapy in cervical dystonia. Mov Disord 17:198-200.
62. Narayan RK, Loubser PG, Jankovic J et al. (1991). Intrathecal baclofen for intractable axial dystonia. Neurology 41:1141-1142.
63. Nutt JG, Hammerstad JP, deGarmo P et al. (1984). Cranial dystonia: double-blind crossover study of anticholinergics. Neurology 34:215-217.
64. Nutt JG, Hammerstad JP, Carter JH et al. (1985). Lisuride treatment of focal dystonias. Neurology 35:1242-1243.
65. Nutt JG, Muenter MD, Aronson A et al. (1988). Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188-194.
66. Nygaard TG, Marsden CD, Duvoisin RC (1988). Dopa-responsive dystonia. Adv Neurol 50:377-384.
67. Obeso JA, Luquin MR (1984). Bromocriptine and lisuride in dystonias. Neurology 34:135-136.
68. Odergren T, Hjaltason H, Kaakkola S et al. (1998). A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6-12.
69. Ohara S, Hayashi R, Momoi H et al. (1998). Mexiletine in the treatment of spasmodic torticollis. Mov Disord 13:934-940.
70. Paret G, Tirosh R, Ben Zeev B et al. (1996). Intrathecal baclofen for severe torsion dystonia in a child. Acta Paediatr 85:635-637.
71. Park YC, Lim JK, Lee DK et al. (1993). Botulinum A toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 8:334-340.
72. Penn RD, Gianino, York MM (1995). Intrathecal baclofen for motor disorders. Mov Disord 10:657-675.
73. Poewe W, Deuschl G, Nebe A et al. (1998). What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64:13-17.
74. Quinn NP, Lang AE, Sheehy MP et al. (1985). Lisuride in dystonia. Neurology 35:766-769.
75. Raja M (1998). Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 19:57-72.
76. Rajput AH. (1973). Levodopa in dystonia musculorum deformans. Lancet 1:432.
77. Ranoux D, Gury C, Fondaray J et al. (2002). Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psych 72:459-462.
78. Rodnitzky RL. (2003) Drug-induced movement disorders in children. Semin Pediatr Neurol 10:80-87.
79. Sampaio C, Ferreira JJ, Simoes F et al. (1997). DYSBOT: a single blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord 12:1013-1018.
80. Segawa M, Hosaka A, Miyagawa F et al. (1976). Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 14:215-233.
81. Stahl SM, Berger PA (1982). Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 32:889-892.
82. Stewart AL, Hays RD, Ware JE (1988). The MOS short-form general health survey: reliability and validity in a patient population. Med Care 26:724-735.
83. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group (2000). A prevalence study of primary dystonia in eight European countries. J Neurol 247:787-792.
84. Thiel A, Dressler D, Kistel C et al. (1994). Clozapine treatment of spasmodic torticollis. Neurology 44:957-958.
85. Tolosa ES, Lai C. (1979) Meige disease: striatal dopaminergic preponderance. Neurology 29:1126-1130.
86. Tsui JK, Eisen A, Stoessl AJ et al. (1986). Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245-247.
87. Tsui JK, Bhatt M, Calne S et al. (1993). Botulinum toxin in the treatment of writer's cramp: a double blind study. Neurology 43:183-185.
88. Van Hilten JJ, Hoff JI, Thang MC et al. (1999). Clinometric issues of screening for responsiveness to intrathecal baclofen in dystonia. J Neural Transm 106:931-941.
89. Vidailhet M, Bouchard C, Jedynak PJ et al. (1993). Acute and long-term response to apomorphine in cranial dystonia. Mov Disord 8:237-239.
90. Volkmann J, Benecke R (2002). Deep brain stimulation for dystonia: patient selection and evaluation. Mov Disord 17:112S-115S.
91. Walker RH, Danisi FO, Swope DM et al. (2000). Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 15:1242-1247.
92. Yoshimura DM, Aminoff MJ, Olney RK (1992). Botulinum toxin therapy for limb dystonias. Neurology 42:627-630.
93. Zuddas A, Cianchetti C (1996). Efficacy of risperidone in idiopathic segmental dystonia. Lancet 347:127-128.
94. Zuddas A, Pintor M, DeMontis N, et al. (1996). Continuous infusion of apomorphine improves torsion dystonia in a boy unresponsive to other dopaminergic drugs. J Child Neurol 11:343-345.